Business ❯ Finance ❯ Investments

Pharmaceuticals

Eli Lilly Acquisitions Stock Market Novo Nordisk Stock Performance Pfizer Indian Pharma Stocks Tariffs Novo Nordisk A/S Clinical Trials Biotechnology Eli Lilly and Company Drug Development Innovative Drugs Generic Drugs Mankind Pharma Sun Pharma Regeneron Pharmaceuticals AbbVie Earnings Reports AstraZeneca PLC Vertex Pharmaceuticals Telix Pharmaceuticals Ltd. Cancer Drug Licensing Partnerships Biosimilars Company Growth Johnson & Johnson Licensing Deals Indian Pharma Companies Dr Reddy's Laboratories Drug Companies AstraZeneca Merck & Co. Drug Approval Market Trends Cohance Lifescience Mergers and Acquisitions Specialty Pharmacy Telix Pharmaceuticals Bristol-Myers Squibb Company Clinical Research Market Reactions Drug Distribution Generic Medicines Biopharmaceuticals Biohaven Aurinia Pharmaceuticals Stock Analysis Sales Forecasts Roche Holding Drug Pricing Company Valuation BioMarin Pharmaceutical Inc. Indian Pharma Company Performance Bristol Myers Squibb Drug Performance HIV Treatments Balaxi Pharmaceuticals Fennec Pharmaceuticals Teva Pharmaceutical Industries Moderna Market Competition TauRx Pharmaceuticals Knight Therapeutics Inc. Psychoactive Compounds Cannabinoids Psilocybin Wockhardt Ltd. Weight Loss Drugs Weight-loss Drugs Vanda Pharmaceuticals Novartis

Eli Lilly Tightens GLP-1 Grip, Guides Up to $83 Billion for 2026

The outlook reflects heavy reliance on two GLP-1 brands despite growing oral competition.

Regeneron Beats Q4 and Charts 2026 Catalysts With FDA Decisions and Phase III Push

Lilly Signs Up to $1.12 Billion Gene-Editing Pact to Tackle Hearing Loss

FDA Approves Vanda’s Nereus, First New Motion Sickness Treatment in Over 40 Years

Bristol Myers Enters 2026 With Eliquis Medicaid Pact, Opdivo Qvantig Rollout, and Divergent Analyst Views

FDA Approves Novo Nordisk’s Wegovy Pill, First Oral GLP-1

BioMarin to Acquire Amicus for $4.8 Billion in Cash

Novo Nordisk Presses India Expansion and Higher-Dose Push as Analyst Views Diverge

Yahoo Finance Highlights Merck and Bristol Myers as Value Plays Outside the GLP-1 Surge

Praxis Relutrigine Study Halted Early for Efficacy as FDA Review Meeting Set

Belite Bio’s Tinlarebant Cuts Stargardt Lesion Growth 36% in Phase 3 Trial

Eli Lilly Becomes First Health Care Company Valued at $1 Trillion

Novartis Lifts Cancer-Drug Forecasts, Targets 5%–6% Sales Growth Through 2030

FDA Rejects Biohaven’s Vyglxia for Spinocerebellar Ataxia

Cardinal Health Leads Earnings-Fueled Rallies After Raising Outlook

FDA Reapproves GSK’s Blenrep for Multiple Myeloma in Narrow Combination Use

Lilly’s Oral GLP-1 Orforglipron Beats Farxiga and Placebo in Two Phase 3 Diabetes Trials

Pfizer Outlines Five-Year Turnaround Bet as Patent Expirations Near

Pfizer–Trump Drug-Pricing Deal and ‘TrumpRx’ Plan Jolt Health-Care Stocks Higher

Pfizer Strikes U.S. Drug-Pricing Pact, Wins Exemption From 100% Import Tariff